The researchers have detailed their complete findings of subcutaneous (SC) vs intravenous (IV) efgartigimod in generalized myasthenia gravis (gMG) from the phase 3 ADAPT-SC trial and initial findings ...
74% of Indian applicants for Canadian study permits in August were rejected, up from 32% in August 2023 Rejection rate for applications overall was 40% Canadian government cites fraud concerns TORONTO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback